Skip to main content

Forma Therapeutics Holdings, Inc.

FMTXDelisted Oct 14, 2022
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001538927

Forma Therapeutics Holdings, Inc. was delisted on Oct 14, 2022; its insiders filed their last Form 4 on Oct 14, 2022; 139 institutions reported holding it in 13F filings for Q3 2022, worth $835.0M in total; HHLR Advisors (Hillhouse) was the only superinvestor holding it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:28 PM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Forma Therapeutics Holdings, Inc., annual
Line itemFY2021FY2020
Period endDec 31, 2021Dec 31, 2020
Filing10-K10-K
ReportedMar 1, 2022Mar 30, 2021
Revenue$0–
Operating expenses$174.0M$124.2M
Research and development$125.7M$93.4M
Selling, general and administrative$48.3M$30.8M
Operating income-$174.0M-$124.2M
Income tax$154.0K-$29.7M
Net income-$173.0M-$70.4M
EPS, basic–$-3.22
EPS, diluted–$-3.22

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Forma Therapeutics Holdings, Inc., annual
Line itemFY2021FY2020
Period endDec 31, 2021Dec 31, 2020
Filing10-K10-K
ReportedMar 1, 2022Mar 30, 2021
Cash and equivalents$77.4M$282.7M
Short-term investments$386.8M$350.4M
Accounts receivable–$0
Total current assets$486.4M$654.4M
Property, plant and equipment$13.9M$1.52M
Total assets$561.1M$681.0M
Accounts payable$4.14M$4.29M
Total current liabilities$35.1M$31.7M
Total liabilities$62.7M$32.7M
Shareholders' equity$498.4M$648.2M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Forma Therapeutics Holdings, Inc., annual
Line itemFY2021FY2020
Period endDec 31, 2021Dec 31, 2020
Filing10-K10-K
ReportedMar 1, 2022Mar 30, 2021
Operating cash flow-$149.8M-$95.4M
Capital expenditures$4.18M$249.0K
Free cash flow-$154.0M-$95.7M
Depreciation and amortization$1.57M$1.28M
Stock-based compensation$22.6M$6.96M
Investing cash flow-$55.4M-$345.8M
Financing cash flow-$459.0K$552.6M
Net change in cash-$205.6M$111.4M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Forma Therapeutics Holdings, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Aug 1, 202247.9M+1.0%SEC
Apr 28, 202247.8M+0.9%SEC
Feb 22, 202247.5M+0.2%SEC
Nov 9, 202147.4M+15.2%SEC
Aug 10, 202147.4M+15.3%SEC
Apr 30, 202147.4M–SEC
Mar 25, 202147.4M–SEC
Nov 6, 202041.2M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.